Prelude Capital Management, LLC Chembio Diagnostics, Inc. Transaction History

Prelude Capital Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 16, 2020	SELL	$3.28 - $5.93 $171,386 - $309,854	-52,252 Closed	0 $0
Q2 2020 Aug 14, 2020	BUY	$3.18 - $15.54 $166,161 - $811,996	52,252 New	52,252 $170,000
Q2 2019 Aug 14, 2019	SELL	$5.56 - $7.85 $1,445 - $2,041	-260 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$5.32 - $7.18 $1,383 - $1,866	260 New	260 $1,000
Q3 2018 Nov 14, 2018	SELL	$9.2 - $11.5 $7,359 - $9,200	-800 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$7.8 - $11.1 $6,240 - $8,880	800 New	800 $9,000

Ticker CEMI
Exchange NASDAQ
Sector Healthcare
Industry Diagnostics & Research
Shares Outstandng 30,224,600
Description
Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or diagnose diseases. The company offers tests for COVID-19, HIV and Syphilis, and Zika virus. It also develops tests for malaria, dengue, chikungunya, Chagas, ebola, leishmaniasis, la...

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Prelude Capital Management, LLC with notifications on news.